Pliant Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing medicines to treat fibrosis—the scarring that makes organs like the lungs and liver stiff. Pliant's name plays on its mission: its therapies aim to make rigid, scarred tissue "pliant," or flexible again. Founded in 2015 by researchers from the University of California, San Francisco, the company targets integrins, proteins that drive the scarring process, with drug candidates for fibrotic and cancer conditions.
Granted 1.03M · Sold 625.9K
Granted 376.3K · Sold 134.2K
Granted 225.9K · Sold 106.3K
Granted 257.1K · Sold 161.0K
Granted 194.8K · Sold 89.3K
Granted 51.9K · Sold 11.3K
Sold 6.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Tepper Robert I +3 co-filers10% owner · 2 transactions | — | 2.36Mas of Dec 2022 | — | — | — |
| Coulie BernardPresident and CEO, Director · 61 transactions | +81.4% | 914.9K | 1.03M | — | 625.9K |
| Cummings Keith LamontChief Financial Officer · 22 transactions | +524.1% | 297.2K | 376.3K | — | 134.2K |
| Hull HansChief Business Officer · 18 transactions | — | 287.3Kas of Jan 2025 | 225.9K | — | 106.3K |
| Lefebvre EricChief Medical Officer · 16 transactions | +75.2% | 240.2Kas of Jan 2025 | 257.1K | — | 161.0K |
| Ouimette MikeGeneral Counsel & Corp. Sec'y · 21 transactions | — | 105.5Kas of Jan 2025 | 194.8K | — | 89.3K |
| Cheung LilyChief Human Resource Officer · 4 transactions | — | 44.8K | 51.9K | — | 11.3K |
| Kuo MinnieChief Operating Officer · 1 transaction | — | 37.8K | — | — | 6.9K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.13M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.